LNAI is the ticker symbol for Lunai Bioworks Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks LNAI with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is LNAI a good stock to buy?

LNAI is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/LNAI.

Where does 13F Pro source LNAI data?

All Lunai Bioworks Inc. fundamentals and ownership data come directly from SEC EDGAR. Lunai Bioworks Inc. files with the SEC under CIK 1527728. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Lunai Bioworks Inc.(LNAI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Lunai Bioworks Inc. (LNAI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LNAI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q1 2026), Lunai Bioworks Inc. reports quarterly revenue of $20.9K, net income of $-2.6M, free cash flow of $-1.0M. Top institutional holders of LNAI by reported 13-F value include Ground Swell Capital, GEODE CAPITAL MANAGEMENT, JANE STREET GROUP, based on the most recent SEC filings. LNAI trades on the Nasdaq exchange and files with the SEC under CIK 1527728. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lunai Bioworks Inc. directly from SEC EDGAR.

Revenue

$20.9K

Net Income

$-2.6M

Free Cash Flow

$-1.0M

LNAI key financials by period

Lunai Bioworks Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2016	10-K	$42.8K	$-1.7M	—

Institutions holding LNAI

Institutional investors reporting a position in Lunai Bioworks Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Ground Swell Capital	53,211	$174.0K	2026-06-30
GEODE CAPITAL MANAGEMENT	24,156	$79.0K	2026-06-30
JANE STREET GROUP	23,683	$77.4K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	16,081	$52.6K	2026-06-30
BlackRock	15,906	$52.0K	2026-06-30
Virtu Financial	12,863	$42.0K	2026-06-30
GROUP ONE TRADING, L.P.	9,500	$31.1K	2026-06-30
VANGUARD FIDUCIARY	8,642	$28.3K	2026-06-30
ROYAL BANK OF CANADA	1,687	$5.0K	2026-06-30
Tower Research Capital (TRC)	1,405	$4.6K	2026-06-30

SEC EDGAR: CIK 1527728 →

Lunai Bioworks Inc.

LNAI

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.